The benefit of the PARP inhibitor in patients with germline BRCA pathogenic variants remains evident 10 years after the first ...
AstraZeneca and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term results ...
Adjuvant olaparib continued to show a strong efficacy benefit in patients with BRCA1/2 mutation–positive, HER2-negative ...
Adjuvant olaparib continued to show a strong efficacy benefit in patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast, according to 6-year data from the OlympiA trial.
Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received placebo after a median ...
Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to ...
Patients with high-risk, BRCA-positive breast cancer who received olaparib after standard treatment continued to have better ...
Updated results from the OlympiA Phase III trial showed AstraZeneca and Merck & Co., Inc’s, known as MSD outside of the US and Canada, LYNPARZA® (olaparib) demonstrated sustained, clinically ...
When Sue Vincent was diagnosed with advanced ovarian cancer, she was told she could have just months to live - until a miracle drug changed everything ...
Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received placebo after a median ...
Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better ...
One year of treatment with the targeted drug olaparib improves long-term survival in women with high-risk, early-stage breast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback